{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:11:41Z","timestamp":1790413901178,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA14520"],"award-info":[{"award-number":["P30 CA14520"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.clml.2017.10.006","type":"journal-article","created":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T09:47:40Z","timestamp":1511776060000},"page":"e61-e67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study"],"prefix":"10.1016","volume":"18","author":[{"given":"Julie E.","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakeesha L.","family":"Carmichael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KyungMann","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9488-1704","authenticated-orcid":false,"given":"David T.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Traynor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae E.","family":"Werndli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Huie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"McFarland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Volk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jules","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie S.","family":"Callander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter L.","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad S.","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.10.006_bib1","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2002.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival","volume":"20","author":"Howard","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.10.006_bib2","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.10.006_bib3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/oxfordjournals.annonc.a059155","article-title":"Patterns of survival in mantle cell lymphoma","volume":"6","author":"Zucca","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2017.10.006_bib4","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.10.006_bib5","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.10.006_bib6","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2017.10.006_bib7","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1093\/annonc\/mdl127","article-title":"Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network","volume":"17","author":"Kahl","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2017.10.006_bib8","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1365-2141.2011.08820.x","article-title":"VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study","volume":"155","author":"Chang","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.10.006_bib9","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2013-08-523845","article-title":"Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)","volume":"123","author":"Chang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.10.006_bib10","author":"National Cancer Institute"},{"key":"10.1016\/j.clml.2017.10.006_bib11","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.10.006_bib12","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in\u00a0vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.10.006_bib13","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/annonc\/mdt070","article-title":"A\u00a0phase II multicenter trial of hyperCVAD MTX\/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213","volume":"24","author":"Bernstein","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2017.10.006_bib14","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2141.2011.08958.x","article-title":"Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi","volume":"156","author":"Merli","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.10.006_bib15","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.10.006_bib16","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.3109\/10428194.2011.580404","article-title":"Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network","volume":"52","author":"Kenkre","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.10.006_bib17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1182\/blood.V128.22.145.145","article-title":"Rituximab maintenance after autologous stem cell transplantation prolongs survival in younger patients with mantle cell lymphoma: final results of the randomized phase 3 LyMa trial of the Lysa\/Goelams Group","volume":"128","author":"Le Gouill","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.10.006_bib18","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","article-title":"Ten-year follow-up after intense chemoimmunotherapy with rituximab-HyperCVAD alternating with rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma","volume":"150","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.10.006_bib19","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","article-title":"Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC\u00a0+ autologous stem-cell support: still very long survival but late relapses do occur","volume":"158","author":"Geisler","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.10.006_bib20","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/blood-2014-08-597914","article-title":"A\u00a0phase 1\/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed\/refractory non-Hodgkin lymphoma","volume":"125","author":"Maddocks","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.10.006_bib21","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1182\/blood.V122.21.3002.3002","article-title":"Minimal residual disease (MRD) status following induction chemo-immunotherapy predicts progression-free survival in mantle cell lymphoma (MCL): CALGB 50403 (Alliance)","volume":"122","author":"Johnson","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.10.006_bib22","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.10.006_bib23","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/j.seminhematol.2011.05.002","article-title":"Minimal residual disease detection in mantle cell lymphoma: technical aspects and clinical relevance","volume":"48","author":"Pott","year":"2011","journal-title":"Semin Hematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017313939?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017313939?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:29:42Z","timestamp":1761870582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265017313939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S2152265017313939"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.10.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}